Notes
Notes cis-Diamminedichloroplatinum(II), i.e., cisplatin, is a potent inorganic anti-tumor drug agent, 2) which is thought to exert its cytotoxic effect by forming intrastrand cross-links between N7 atoms of adjacent guanines of genomic DNA. 2, 3) When cisplatin is administered intravenously, however, it is exposed to various endogenous S-donor proteins. Platination of such proteins leads serious side effects, such as nephrotoxicity. 4) In addition, some cisplatin-resistant tumors such as A2780cisR 5) and SKOV-3 6) have elevated levels of glutathione. Therefore, the interaction between anti-tumor platinum complexes and S-donor proteins plays an important role in drug-resistance and the appearance of side effects. 7) Nuclear magnetic resonance (NMR) spectroscopy is a powerful tool to investigate reactions between anti-tumor platinum complexes and S-donor proteins or peptides. Berners-Price and Kuchel studied the reactions of cis and transdiamminedichloroplatinum(II) with reduced glutathione by means of 1 Pt-enriched samples are expensive and hard to prepare, especially for modern sophisticated platinum complexes. For example, oxalato(1R,2R-cyclohexanediammine)platinum(II) (oxaliplatin), which is a third-generation platinum anti-tumor drug, has no replaceable NH 3 groups.
As an alternative approach, we have studied the properties of anti-tumor platinum complexes in a physiological environment by employing extended X-ray absorption fine structure (EXAFS) methodology. An EXAFS signal at the Pt L III edge (11562 eV) of anti-tumor platinum complexes can be detected without any isotope-labeling. In addition, the absence of platinum ions in a biological system allows us to detect the EXAFS signal of anti-tumor platinum complexes selectively even in highly heterogeneous media, such as culture media and in cells. Analysis of the EXAFS signal using a suitable theoretical model affords direct information about coordinating species and distances, unlike NMR spec- ment with the composition. The r i values for Pt-N and Pt-Cl were 2.04 and 2.34 Å, respectively, which also accorded well with those derived from X-ray crystallography 10) (2.00, 2.32 Å, respectively). The N S and r S values for K 2 [Pt(SCN) 4 ] were determined to be 3.8 and 2.33 Å, respectively, and were also close to those derived from X-ray crystallography 11) (4, 2.32 Å, respectively). Hence, we assumed an amplitude reduction factor S 0 2 of 1 in the standard EXAFS equation. In addition, analyses of the EXAFS oscillation using the F O (k), F S (k), F O (k) and F S (k) functions afforded essentially the same structural parameters (#2 and 3 in Table 1 ) as those given by the F N (k), F Cl (k), F N (k) and F Cl (k) functions. Therefore, we used the F N (k), F Cl (k), F N (k) and F Cl (k) functions for analyses of the reactions of anti-tumor platinum complexes with reduced glutathione.
Reaction of cisplatin with reduced glutathione was carried out in phosphate-buffered saline (PBS) at 37°C. Figure 1a shows Fourier transforms of k 3 -weighted Pt L III EXAFS oscillations (k 3 c(k)) of the reaction mixture at each reaction time. Two peaks were found at ca. 1.6 and 2.0 Å (before phase-shift correction) before the addition of reduced glutathione (tϭ0 min). These were assigned to back-scattering contributions of N and Cl atoms coordinated to Pt ion, respectively. As the reaction proceeds, the peak at 1.6 Å decreased, while the peak at 2.0 Å increased monotonically. After 180 min, the contribution from O/N became too small to fit, then the Fourier transform showed essentially a single peak at 2.0 Å.
The reaction rate of carboplatin with glutathione was significantly slower than that for cisplatin. Therefore the concentrations of carboplatin and reduced glutathione were adjusted to be twice those in the case of cisplatin. Figure 1b shows Fourier transforms of k 3 c(k) functions of the reaction mixture at each reaction time. At tϭ0 min, only one peak was found at ca. 1.6 Å, and this can be attributed to backscattering contributions from N/O ligands. After addition of reduced glutathione, a new peak appeared at ca. 2.0 Å, and finally (at tϭ930 min), the peak at 1.6 Å disappeared.
Each k 3 c(k) function obtained was fitted to the standard EXAFS equation using the F N (k) and F N (k), and F Cl (k) and F Cl (k) functions. ues, however, decreased monotonically with the progress of both reactions, while the N Cl/S value increased from 2.2 to 3.5 for cisplatin and from 1.1 to 4.1 for carboplatin. This indicated that all the ligands were substituted with the S atom of reduced glutathione. Coordination of S atom releases NH 3 at the trans position. These phenomena and kinetics are good in accordance with the results of the NMR study reported by Berners-Price and Kuchel. 8) In the case of carboplatin, the ligands NH 3 and 1,1-cyclobutanedicarboxylato anion were also replaced by the S atom of reduced glutathione, but the substitution rate was significantly slower than that of cisplatin because of the chelating effect of the 1,1-cyclobu- 
2. tanedicarboxylato anion.
The ultimate product of the reaction is thought to be a high-molecular-weight m-S bridged species. In the EXAFS analysis, however, there was no significant contribution from vicinal Pt ions. This may be because of the longer distance between Pt ions and the absence of an efficient shade effect.
In conclusion, the EXAFS analyses of the reactions of cisplatin and carboplatin with reduced glutathione were performed by using standard theoretical methods without any tedious isotope-labeling. The results were good in agreement with those obtained by NMR analysis of isotope-labeled compounds. This technique should therefore be useful to examine the reactions of a variety of anti-tumor platinum complexes with endogenous S-donor proteins or peptides even in highly heterogeneous media, such as in culture.
Experimental
General Cisplatin and K 2 [Pt(SCN) 4 ] were prepared according to the conventional method. Carboplatin was purchased from STREM Chemicals, Inc. Reduced glutathione was purchased from Wako Pure Chemicals Inc. Dulbecco's phosphate-buffered saline (PBS) was purchased from Nacalai tesque.
Reaction of Cisplatin with Reduced Glutation Cisplatin (150 mg, 0.5 mmol) was dissolved in PBS (50 ml) by heating. After the solution had cooled, it was stirred at 37°C. Reduced glutathione (1.53 g, 5 mmol) was added to initiate the reaction.
Reaction of Carboplatin with Reduced Glutation Carboplatin (153 mg, 0.4 mmol) was dissolved in PBS (20 ml). Reduced glutathione (1.24 g, 4 mmol) was added to initiate the reaction.
EXAFS Measurement EXAFS measurements were performed at beam lines 10B and 7C of the Photon Factory of the High Energy Acceleration Research Organization (KEK-PF), Tsukuba, Japan. The ring current was 300-450 mA, and the storage ring was operated with an electron energy of 2.5 GeV. The experiments at the Pt L III edge (11562 eV) were carried out at room temperature in the transmission mode on samples in PBS solution in a glass cell (path lengthϭ10 mm). The EXAFS oscillation (k 3 c(k)) was extracted using standard procedures for preedge subtraction, data normalization, and spline removal. The obtained k 
, and s i represent the amplitude reduction factor, the interatomic distance, the coordination number, the back-scattering amplitude, the phase shift, and the Debye-Waller factor of the i-th shell, respectively, and k is the photoelectron wave vector defined as kϭ
1/2 with the threshold energy E 0 . The F i (k) and F i (k) functions for the single scattering pathways were calculated by means of the FEFF 8.2 program. 9) All calculations were performed with REX2000 ver.135 2.0.7 (Rigaku Co.). 
